EGFR and neoplasm: Recurrent GBM patients that harboured an EGFR amplification were treated with a combination of TMZ and anti-EGFR monoclonal antibody coupled to a toxin (ABT-414; DEPATUX-M®) [25,26], These exceptional responders included one patient with a durable response beyond 40 months in addition to 4 and 9 patients with a reduction in tumor volume of 25–50% and 25%, respectively, out of a total of 60 patients that received this treatment [27].